Alerts will be sent to your verified email
Verify Email
SANJIVIN
|
Sanjivani Paranteral
|
Parnax Lab
|
Vijaypd Ceutical
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Quarterly Sales Volume - Injectables
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Orals
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Nutraceuticals
|
n/a | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
14.47 % | 11.65 % | 14.91 % |
|
5yr average Equity Multiplier
|
-1.07 | 2.74 | 1.77 |
|
5yr Average Asset Turnover Ratio
|
1.28 | 1.01 | 1.87 |
|
5yr Avg Net Profit Margin
|
11.86 % | 4.21 % | 4.49 % |
|
Price to Book
|
4.1 | 2.04 | 0.0 |
|
P/E
|
22.27 | 14.67 | 38.14 |
|
5yr Avg Cash Conversion Cycle
|
9.84 Days | 30.1 Days | 112.12 Days |
|
Inventory Days
|
50.77 Days | 45.64 Days | 39.42 Days |
|
Days Receivable
|
53.66 Days | 61.56 Days | 81.32 Days |
|
Days Payable
|
138.53 Days | 72.37 Days | 8.63 Days |
|
5yr Average Interest Coverage Ratio
|
21.37 | 2.99 | 4.03 |
|
5yr Avg ROCE
|
-90.78 % | 17.86 % | 26.57 % |
|
5yr Avg Operating Profit Margin
|
14.73 % | 13.13 % | 8.04 % |
|
5 yr average Debt to Equity
|
-0.19 | 1.12 | 0.68 |
|
5yr CAGR Net Profit
|
12.42 % | n/a | 92.84 % |
|
5yr Average Return on Assets
|
15.34 % | 4.42 % | 8.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.26 % | 72.3 % | 56.43 % |
|
Share Pledged by Promoters
|
0.0 | 9.41 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.38 % | 0.0 | -21.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Sanjivani Paranteral
|
Parnax Lab
|
Vijaypd Ceutical
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|